From the run-in period to week @ , both treatments improved symptoms ( mean change -@ -LSB- -@ to -@ -RSB- in the as-needed beclometasone-formoterol group vs -@ -LSB- -@ to -@ -RSB- in the as-needed salbutamol group , difference -@ -LSB- -@ to @ -RSB- ; p = @ ) , percentage of asthma control days ( @ % -LSB- @ to @ -RSB- vs @ % -LSB- @ to @ -RSB- , respectively , -@ -LSB- -@ to @ -RSB- ; p = @ ) , use of reliever ( -@ -LSB- -@ to -@ -RSB- vs -@ -LSB- -@ to -@ -RSB- , respectively , -@ -LSB- -@ to @ -RSB- ; p = @ ) , and lung function ( FEV@ , @ -LSB- @ to @ -RSB- vs @ -LSB- @-@ -RSB- , respectively , @ -LSB- -@ to @ -RSB- ; p = @ ) , and were well tolerated ( patients with serious adverse events , @ -LSB- @ % -RSB- and @ -LSB- @ % -RSB- , respectively ) .